<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02593201</url>
  </required_header>
  <id_info>
    <org_study_id>PPDNA</org_study_id>
    <nct_id>NCT02593201</nct_id>
  </id_info>
  <brief_title>The Efficacy of Prolonged Antibiotic Therapy for the Prevention of Relapsing Peritonitis in Peritoneal Dialysis Patients With High Dialysis Effluent Bacterial DNA Fragment Levels</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peritoneal dialysis (PD) is the first-line treatment of end stage renal disease (ESRD) in
      Hong Kong. Despite the advances in antibiotic therapy and connecting system, recurrent
      peritonitis remains the major cause of peritoneal failure. A recent study showed that an
      elevated bacterial DNA fragment levels in PD effluent 5 days prior to the completion of
      antibiotics predicts the development of relapsing or recurrent peritonitis episodes. We
      hypothesize that prolonged antibiotic therapy in PD patients with peritonitis and high PD
      effluent bacterial DNA fragment levels could prevent the development of relapsing and
      recurrent peritonitis. We plan to conduct a randomized control study of 360 patients with PD
      peritonitis. After inform consent, they will be randomized to receive one additional week of
      the effective antibiotic treatment (the Preemptive Treatment Group) or no additional
      treatment (the Control Group). Specimens of PD effluent will be collected 5 days prior to the
      completion of antibiotics for the measurement of bacterial DNA fragments. All patients will
      be followed for 6 months after completion of antibiotic therapy for the development of
      relapsing, recurrent, or repeat peritonitis episodes. Our study will determine the efficacy
      of a test-before-treat algorithm that could reduce the incidence of relapsing and recurrent
      peritonitis and, at the same time, minimize the unnecessary use of prolonged antibiotic
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2016</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relapsing peritonitis episodes</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>repeat peritonitis episodes</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>recurrent peritonitis episodes</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>peritonitis that requires hospitalization</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need of catheter removal</measure>
    <time_frame>6 months</time_frame>
    <description>by record review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need of conversion to long-term hemodialysis</measure>
    <time_frame>6 months</time_frame>
    <description>by record review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death due to peritonitis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">358</enrollment>
  <condition>Peritoneal Dialysis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One extra week of antibiotic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>No extra antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended antibiotics (cefazolin or ceftazidime)</intervention_name>
    <description>To continue with the existing effective antibiotic therapy for one extra week</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual antibiotics (cefazolin or ceftazidime)</intervention_name>
    <description>Usual duration of effective antibiotic therapy therapy</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with peritoneal dialysis-related peritonitis

        Exclusion Criteria:

          -  Patients with fungal peritonitis

          -  Patients with obvious surgical problems and require laparotomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Medicine &amp; Therapeutics, Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 29, 2015</study_first_submitted>
  <study_first_submitted_qc>October 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2015</study_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Cheuk-Chun SZETO</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

